Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening
7.11.2023 16:30:00 EET | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM . This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.
Screening of a large panel of patient-derived organoids is enabled using Crown Bioscience’s unique assay-ready (AR) organoid technology. Recent posters presented at the AACR annual meeting and ANE international conference 2023 demonstrate the performance of assay-ready organoids against freshly prepared organoids – the traditional methodology. The study demonstrated the utility of OrganoidXplore and revealed:
- Highly Robust Performance: Both the assay-ready and original methods consistently performed with high accuracy across multiple assays.
- Accelerated Timelines and Reduced Costs: OrganoidXplore slashed project timelines by two-thirds, when compared to standard methods.
- Reliable and Reproducible Drug Response Comparisons: Both methods showed analogous results in cell viability (CTG) and high content imaging (HCI) assays when tested with standard drugs such as paclitaxel, carboplatin, and cisplatin.
OrganoidXplore transcends traditional 2D cell culture systems in terms of patient relevance, heralding a significant leap in preclinical drug screening. By accurately replicating the genomic, morphological, and pathophysiological attributes of original tumors, researchers are now equipped to screen against an extensive range of predictive models. Results can be obtained within an expedited timeframe of just six weeks, magnifying research speed three-fold and anchoring its promise on the robustness and reproducibility of its advanced assay-ready technology.
Researchers can choose between a comprehensive Full Panel or a specialized KRAS Panel to meet their specific goals. The Full Panel currently comprises 50 organoid models covering seven cancer indications, which are also available as companion Patient-Derived Xenografts (PDX). The KRAS Panel specifically targets four cancer indications, with 25 models covering a broad range of KRAS mutations. These models are also available as PDX, allowing for a seamless transition to follow-on studies.
In combination with comprehensive next-generation sequencing (NGS) characterization, including whole exome sequencing (WES) and RNA sequencing (RNAseq), OrganoidXplore enables expedited biomarker identification, highly relevant mechanism of action studies, selection of indications and/or models, investigation of drug repurposing, and improved patient stratification.
Leo Price, PhD, Senior Vice President, In Vitro and Head of Crown Bioscience Netherlands, said: “OrganoidXplore addresses the exacting demands of pioneering research initiatives by offering a diverse selection of models that cover a wide spectrum of genetic backgrounds and mutations. Thanks to the implementation of innovative organoid cryopreservation technology automation and assay automation, OrganoidXplore’s precision, speed, and reproducibility are unrivaled.”
Crown Bioscience remains steadfast in its commitment to driving innovations in oncology research, evidenced by the introduction of OrganoidXplore, designed with the mission to accelerate drug discovery.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology and immuno-oncology. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology, offering over 600 organoid models spanning 22 cancer indications. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia.
For more information or to get in touch, please visit www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231107255253/en/
Contact information
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enry’s Island Unveils “Enry’s Island Adventures”: Venture Capital Becomes a Videogame and Launches the “Strap” Movement on Kickstarter3.4.2026 10:47:00 EEST | Press release
Enry’s Island SpA (WBAG: EIOS), the world’s first publicly traded Venture Builder, today announced the upcoming Kickstarter launch of Enry’s Island Adventures (EIA), developed by its New York-based portfolio company, Enry’s Island Adventures LLC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402548535/en/ The game is designed to make venture capital accessible to new generations, transforming startup creation into an engaging and social gaming experience. After three years of R&D, EIA introduces a "bleisure" model (business + leisure): players learn to launch and manage startups through gameplay that includes real business KPIs, a customizable and evolving personal island, synchronous and asynchronous multiplayer modes, social events, and community-driven seasonal missions. The “VC revolution”: teaching and democratizing through play "I agree with Elon Musk that the best way to teach is through a video game, and this is
SES Announces Results of the Annual General Meeting2.4.2026 17:49:00 EEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 17:00:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those business outcomes; establish a structured runway to plan, test, and strategically time the deployment
Andersen Consulting Adds Multiplica2.4.2026 16:30:00 EEST | Press release
Andersen Consulting enters into a Collaboration Agreement with Multiplica, a digital consulting firm that helps organizations design, build, and scale impactful digital experiences. Founded in Spain with a presence in Latin America and the U.S., Multiplica focuses on user research and discovery, customer experience research, digital strategy, data modeling and analysis, report automation and data visualization, conversion rate optimization, product design, and user experience design. The firm helps organizations accelerate digital transformation by building digital capabilities, teams, and assets that advance expertise across digital products, consulting, and talent development. Multiplica enables clients to forecast emerging trends in digital experience and transform their businesses through enhanced digital channels and customer engagement. “Collaborating with Andersen Consulting represents an exciting opportunity to extend our reach and impact,” said David Boronat, CEO of Multiplica
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 16:00:00 EEST | Press release
Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly. Spend Better. That is our north star, and that is what our platform is built to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom